Insights
Integrated Specialty Care
Posters
This study assesses the impact of a structured approach to increase engagement with health system specialty pharmacy patients who were previously lost to follow up.
Posters
This study assesses the impact of technology-based and refill technician workflow interventions on health system specialty pharmacy staff productivity.
Posters
This study assesses the pharmacist impact within an ATTR-CM specialty program by characterizing documented interventions and associated outcomes.
Posters
This study assesses the patient perception of treatment experience observed during routine specialty pharmacy interactions among tafamidis-treated ATTR-CM patients.
Posters
This study shows how the Shields clinical pharmacist career ladder provides structured growth pathways and offers incentives that align with organizational and employee goals.
Posters
This study assesses the impact of an integrated health system specialty pharmacy model on GLP-1 RA access and adherence in adult patients with obesity.
Posters
This study describes the CoP program and demonstrates how it enriches the clinical roles supporting health system specialty pharmacies through disease knowledge and professional development.
Posters
This study assess the impact of a health system specialty pharmacy program on operational and clinical outcomes for patients on hGH.
Posters
This poster explores the ability of integrated health system specialty pharmacies to mitigate barriers faced by patients taking Glucagon-like peptide-1 receptor agonists (GLP-1 RAs).
Articles
Improve specialty outcomes and access to therapy with Shields’ platform that combines embedded clinical expertise with AI-enabled automation and intelligent workflows to drive connected performance.
Articles
Starting January 1, 2027, the 340B landscape may shift following the Health Resources and Services Administration’s (HRSA) implementation of the revised 340B Rebate Model Pilot Program (“Pilot Program
Posters
Mavacamten is a first in class myosin inhibitor used in the treatment of obstructive hypertrophic cardiomyopathy (oHCM).
Turn insight into impact with a partner that delivers proven results for health systems and patients.
